Role Summary
Vice President, Head of United States (U.S.) Medical Affairs will lead the development and execution of Revolution Medicinesโ US Medical Affairs strategy, aligning with global and US objectives. The role involves building and leading the US medical affairs team, embedding US medical considerations into the global medical strategy, and supporting launch planning and market access initiatives. The position requires strong leadership, cross-functional collaboration, and a deep understanding of the US oncology landscape.
Responsibilities
- Lead the development and execution of the US Medical Affairs strategy and tactical plans for the portfolio, ensuring alignment with global objectives and US market needs.
- Build and lead the US Medical Affairs team, collaborating with cross-functional leaders to ensure clear, aligned objectives.
- Serve as the US medical expert across the oncology portfolio, guiding clinical development, market access, regulatory strategy, and commercialization plans.
- Support Clinical Operations with appropriate US site selection, quality, and enrollment in line with regulatory/compliance requirements.
- Establish and maintain collaborative relationships with KOLs, academic institutions, cooperative groups, professional societies, and healthcare providers.
- Oversee medical input into payer engagement strategies and external expert consultations to support market access and reimbursement.
- Lead planning and development of expanded access programs in the US region, as appropriate.
- Provide US input into scientific communication activities, including publication planning, congress strategy, and medical education programs.
- Provide US input into Real-World Evidence (RWE) initiatives, Phase IV studies, and Investigator-Sponsored or Collaborative Research.
- Offer US medical insight and leadership on cross-functional teams, including Global Medical Affairs, Clinical Operations, US Commercial, and US Market Access.
- Support US launch planning and ensure all medical activities adhere to ethical, regulatory, and compliance standards.
- Support medical review of non-promotional and promotional materials and contribute to internal training and capability building for US medical teams.
- Represent the company at appropriate US industry conferences and events.
- Develop and manage the US Medical Affairs budget.
- Foster a culture consistent with the global RevMed values and vision/mission.
Qualifications
- Required: Advanced scientific degree (MD, PhD, or PharmD) with specialization or significant experience in oncology.
- Required: Minimum 10 years of relevant Medical Affairs experience within oncology, including regional or global leadership roles.
- Required: Proven ability to lead medical strategy and engage effectively with external oncology experts and stakeholders.
- Required: Demonstrated ability to build and lead a high-performing medical affairs team.
- Required: Strong knowledge of the US oncology landscape, including regulatory frameworks, treatment guidelines, and reimbursement pathways.
- Required: Experience with scientific data generation, clinical trial interpretation, and communication of complex data to diverse audiences.
- Required: Ability to work independently in a matrixed, international environment.
- Required: Ability to create and nurture a strong culture of collaboration and authenticity to extend and replicate the RevMed culture.
- Required: Highly organized and motivated with excellent communication, presentation, and interpersonal skills.
- Required: Strong team orientation and commitment to continuous self and team development.
- Required: Strong leadership and influencing skills with the ability to create a clear sense of direction.
- Required: Ability to multi-task and flexibly lead; willingness to learn new therapeutic areas and technologies.
- Required: Thrive in a fast-paced, dynamic small company environment with the ability to adjust priorities and workload.
- Preferred: Experience with an oncology launch is desirable.
- Preferred: Experience in gastrointestinal and lung cancers is preferred.